International Cancer Conference Journal最新文献

{"title":"Resistant PRL-secreting PitNET associated with breast carcinoma: a case report and literature review.","authors":"Roxana-Ioana Dumitriu-Stan, Iulia-Florentina Burcea, Valeria Nicoleta Nastase, Raluca Amalia Ceausu, Marius Raica, Catalina Poiana","doi":"10.1007/s13691-024-00741-y","DOIUrl":"10.1007/s13691-024-00741-y","url":null,"abstract":"<p><p>In several studies, hyperprolactinemia has been associated with increased breast cancer risk. Evidence shows that prolactin (PRL) is linked to mammary tumorigenesis, especially in postmenopausal patients, but the data remain controversial. We present a case of a 67 year-old patient with a resistant PRL-secreting PitNET who subsequently developed breast cancer. The patient was known to have persistent high PRL levels despite multimodal treatment (surgery, radiotherapy, and high doses of cabergoline). The tumor specimens obtained after transsphenoidal intervention were histologically and immunohistochemically examined for the following parameters: anterior pituitary hormones, the ki-67 labeling index, CAM 5.2 expression, ER ∝ expression, and somatostatin receptors, which revealed a densely granulated tumor with intense positivity for PRL and ER ∝ , a ki-67 labeling index of 6% and negative MGMT expression. Years later, the patient was diagnosed with breast carcinoma. Histopathological and immunohistochemical examination of the tumor specimen obtained after radical mastectomy confirmed ductal invasive breast cancer with negative immunostaining for prolactin receptors (PLRr) but positive immunostaining for estrogen (ER) and progesterone receptors (PGR) and a ki-67 labeling index of 8%. PRL is involved in mammary development and differentiation, which leads to lactation, the major driver during pregnancy, by regulating ovarian progesterone production. On the basis of the physiological actions of PRL, a role for this hormone in breast cancer has been suggested. Few cases of different types of breast carcinoma associated with hyperprolactinemia due to a pituitary tumor have been reported in the literature. The association between hyperprolactinemia and the risk of breast carcinoma is not well understood. Immunohistochemistry evaluation of PLRr can be helpful to provide information in these cases.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"97-106"},"PeriodicalIF":0.5,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anastrozole-induced interstitial lung disease followed by tamoxifen-induced agranulocytosis in a patient with breast cancer.","authors":"Maki Juge, Takako Imada, Mizuki Hirose, Ken Sato","doi":"10.1007/s13691-024-00742-x","DOIUrl":"10.1007/s13691-024-00742-x","url":null,"abstract":"<p><p>A 70-year-old woman with the breast cancer exhibited interstitial lung disease 20 months after the administration with anastrozole, which was performed as the post-operative adjuvant therapy. The drug-induced lymphocyte stimulation test revealed that anastrozole was responsible for the development of interstitial lung disease in this patient. The interstitial lung disease was effectively treated by prednisolone. Then, tamoxifen was used as an alternative therapy, resulting in the occurrence of agranulocytosis 24 days after the administration with tamoxifen. Both anastrozole and tamoxifen are widely used and are highly effective drugs for the treatment of breast cancer. However, the current patient shows that both drugs could cause, albeit very rare, serious side effects in some patients.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"91-96"},"PeriodicalIF":0.5,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors.","authors":"Akiho Nagayama, Chiho Miyagawa, Yoko Kashima, Mamiko Ohta, Tomoyuki Otani, Takashi Kurosaki, Kohsuke Isomoto, Chiaki Inagaki, Takayuki Takahama, Kimio Yonesaka, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa, Noriomi Matsumura","doi":"10.1007/s13691-024-00740-z","DOIUrl":"10.1007/s13691-024-00740-z","url":null,"abstract":"<p><p>A 69-year-old multiparous postmenopausal woman had undergone bilateral total hip arthroplasty 17 years ago. Computed tomography showed a mature teratoma of 10 cm in the pelvis. Subsequently, she presented with symptoms of hoarseness and weight loss, along with evidence of malignant transformation of the same tumor in the pelvis and multiple enlarged lymph nodes. Bilateral adnexectomy was performed via laparotomy, yet peritoneal dissemination persisted. The ovarian tumor's histopathological diagnosis was mature teratoma with squamous cell carcinoma. Additionally, the mediastinal lymph nodes biopsy revealed poorly differentiated carcinoma. Comprehensive genomic profiling testing of the ovarian tumor showed pathogenic variants of <i>TP53</i> and <i>PTEN</i>, a high tumor mutational burden, homologous recombination deficiency and the absence of human papilloma virus. The similar genomic testing of the mediastinal tumor revealed three variants of uncertain significance that were common to the ovarian tumor. However, no variants of <i>TP53</i> or <i>PTEN</i> were identified. Following surgery, she demonstrated a partial response to six cycles of conventional paclitaxel and carboplatin. She then received maintenance treatment with niraparib; however, disease progression subsequently occurred. The patient was treated with pembrolizumab and is currently receiving treatment with a partial response. Previous reports have demonstrated the efficacy of immune checkpoint inhibitors in 5 out of 6 cases of malignant transformation of mature teratomas, and this treatment appears to be a promising strategy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-024-00740-z.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"85-90"},"PeriodicalIF":0.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal anastomotic leakage after conversion surgery for advanced endometrial cancer treated with lenvatinib plus pembrolizumab: a case report.","authors":"Akitoshi Yamamura, Junzo Hamanishi, Koji Yamanoi, Masumi Sunada, Mana Taki, Rin Mizuno, Yukiko Okada, Ryusuke Murakami, Yuki Aisu, Hisatsugu Maekawa, Ken Yamaguchi, Masaki Mandai","doi":"10.1007/s13691-024-00739-6","DOIUrl":"https://doi.org/10.1007/s13691-024-00739-6","url":null,"abstract":"<p><p>The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low anterior rectal resection for unresectable EC following LP therapy is unknown. A 37-year-old woman was referred with unresectable EC with pleural fluid, peritoneal dissemination, and ascites. After the failure of first-line platinum-based chemotherapy, she was administered LP as second-line treatment. After 10 treatment cycles, uterine and peritoneal tumors significantly reduced in size, except the left ovarian metastatic tumor which became slightly larger. Cytoreductive surgery, including low anterior resection of the rectum and colorectal anastomosis, achieved complete resection. However, on postoperative day 11, the patient experienced an anastomotic leakage around the colorectal anastomosis site, necessitating a double-barreled colostomy and percutaneous drainage. She was discharged 15 days after the second surgery and resumed LP therapy after 44 days following the second surgery. We report a case in which conversion surgery after LP therapy was conducted for unresectable advanced endometrial cancer. Our findings indicate that if bowel resection is required, a longer preoperative withdrawal period may be necessary to prevent postoperative anastomotic leakage.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"64-71"},"PeriodicalIF":0.5,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma.","authors":"Yumi Inukai-Motokura, Kiichiro Ninomiya, Takahiro Baba, Hiroki Omori, Tetsuya Takeguchi, Mari Uno, Yoshiyuki Ayada, Takehiro Tanaka, Yoshinobu Maeda, Kadoaki Ohashi","doi":"10.1007/s13691-024-00737-8","DOIUrl":"https://doi.org/10.1007/s13691-024-00737-8","url":null,"abstract":"<p><p>Pulmonary sclerosing pneumocytoma (PSP) is a rare form of lung cancer that occasionally presents with lymph node and extrapulmonary metastases, and multiple lesions. The treatment of metastatic PSP remains undefined. This study reports the case of a 48-year-old female patient diagnosed with PSP following surgical intervention for a solitary nodule in the left lower lobe. Four years later, recurrence occurred in the left hilar and mediastinal lymph nodes, necessitating an additional resection. Concurrently, sacral metastases developed and required palliative radiotherapy. Genetic analysis identified an <i>AKT1</i> E17K mutation, characteristic of PSP, and absence of programmed cell death ligand 1 (PD-L1) expression in the tumor. Two years post-recurrence, the tumor recurred in the left mammary gland and mediastinal lymph nodes. Combination immunotherapy with ipilimumab and nivolumab yielded a significantly positive response in this metastatic PSP case. This is the first reported case of successful treatment of multiple distant metastatic PSP with ipilimumab and nivolumab, following the failure of various local treatments. Further case series are warranted to validate the efficacy of immunotherapy in metastatic PSP.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"60-63"},"PeriodicalIF":0.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful osimertinib treatment for Meckel's cave metastasis: a case report.","authors":"Kazuhiko Iwasaki, Satoshi Watanabe, Yusuke Ikku, Seiji Yano","doi":"10.1007/s13691-024-00736-9","DOIUrl":"10.1007/s13691-024-00736-9","url":null,"abstract":"<p><p>Osimertinib has emerged as the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations, offering improved tolerability and demonstrating superior efficacy against brain metastases in comparison with other tyrosine kinase inhibitors. The Meckel's cave is a dural recess in the posteromedial part of the middle cranial fossa that acts as a conduit for the trigeminal nerve between the anterior pontine cisterna and the cavernous sinus, and houses the Gasserian ganglion and proximal radicle of the trigeminal nerve. Trigeminal neuropathy, characterized by numbness and dysesthesia of the skin and mucous membranes of the face, poses diagnostic challenges and often requires differentiation from conditions, such as compression neuropathy, inflammation, and drug-induced reactions. Here, we report the case of Meckel's cave metastasis. She presented headache, anorexia, left facial numbness, and pain indicative of trigeminal neuropathy. Imaging revealed metastasis to Meckel's cave, consistent with her clinical symptoms. EGFR L858R mutation was detected by primary lesion of the lung DNA analysis. Treatment with osimertinib led to regression of the primary tumor and improvement of the trigeminal neuropathy within 3 months. Importantly, our review of the relevant literature identified only two similar cases with metastasis of lung adenocarcinoma to Meckel's cave. Ours was the only case in which symptom resolution was achieved. We underscore the utility of MRI and PET/CT studies in evaluating trigeminal-related symptoms and discuss imaging characteristics that may aid in their differentiation.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"56-59"},"PeriodicalIF":0.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foreign body granuloma caused by gauze fibers: a rare cause of chronic postoperative ileus following cytoreductive surgery for pseudomyxoma peritonei.","authors":"Cécile Loaec, Tessereau Jean-Yves, Alexis Dumont, Camille Lemarie","doi":"10.1007/s13691-024-00733-y","DOIUrl":"10.1007/s13691-024-00733-y","url":null,"abstract":"<p><p>Foreign body granuloma (FBG) is an inflammatory reaction to an exogenous agent. This entity is well known on the cutaneous organ but very rarely described in the abdominal cavity. We report three clinical cases of intraperitoneal FBG following major debulking of pseudomyxoma and intraperitoneal hyperthermia chemotherapy. The symptoms of FBG were a prolonged postoperative ileus (POI) requiring complex repeat surgery. The intestine was retracted by fibrous tissue with several small granulomas at the center. The granulomatous reaction was established by histopathology and the foreign body was clearly and secondarily identified as gauze fibers. Such cases have never been described before and open discussion is needed about the obstruction mechanism, the role played by large peritonectomies, the impact of the COVID-19 epidemic on malfunctions in material devices usually considered safe, and methods to ensure patient safety.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"50-55"},"PeriodicalIF":0.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mini-open periacetabular cementoplasty for periacetabular bone metastasis: a report of two cases.","authors":"Masahiro Kirisawa, Tomoaki Torigoe, Yasuo Yazawa, Takuya Watanabe, Yuho Kadono","doi":"10.1007/s13691-024-00731-0","DOIUrl":"https://doi.org/10.1007/s13691-024-00731-0","url":null,"abstract":"<p><p>Bone metastasis in the periacetabular region usually causes severe pain and functional disability. Some surgical procedures, such as the Harrington surgery and percutaneous cementoplasty, have been reported as treatment options for periacetabular bone metastases with limited efficacy. The former is highly invasive, while the latter may not allow the injection of a sufficient amount of cement. Here we report two surgical cases using a new modified surgical method (mini-open periacetabular cementoplasty: MO-PAC) consisting of tumor curettage and cementoplasty through a small incision.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"39-45"},"PeriodicalIF":0.5,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian carcinosarcoma of heterologous type occurring in an endometriotic cyst with 3-year recurrence-free survival: a case report and literature review.","authors":"Mikinari Sumino, Hirotsugu Hashimoto, Nakako Sato, Mihiro Dejima, Yuko Sasajima, Masatoshi Sugita, Teppei Morikawa","doi":"10.1007/s13691-024-00728-9","DOIUrl":"10.1007/s13691-024-00728-9","url":null,"abstract":"<p><p>A 41-year-old premenopausal woman presented to our hospital with lower abdominal distention and epigastralgia. An ovarian endometriotic cyst was noted when she was 30 years, and was only followed up until she was 36 years. Suspecting rupture of an ovarian tumor, left adnexectomy was performed. The left ovarian tumor was diagnosed as an ovarian carcinosarcoma of the heterologous type occurring in the endometriotic cyst. The carcinosarcoma was composed of an admixture of high-grade carcinomatous and sarcomatous components, including rhabdomyosarcoma. Thereafter, secondary surgery was concluded, which confirmed the tumor stage to be pT1c3. She postoperatively received 6 cycles of docetaxel/carboplatin as adjuvant chemotherapy and achieved recurrence-free survival for 40 months. Among ovarian carcinosarcomas, cases occurring in endometriotic cysts are particularly rare and may have a relatively good prognosis, because tumor cells, especially sarcoma components, tend to be confined to the ovaries. Pathological estimation of the origin of carcinosarcoma is important, because it appears to correlate with prognosis.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"21-26"},"PeriodicalIF":0.5,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate ductal adenocarcinoma with MLH1 copy number loss, microsatellite instability high and BRCA2 mutation.","authors":"Jianping Li, Tie Chong, Li Wang, Zihao Li, Yaofeng Jin, Yan Chen, Dujuan Liu, Lingna Jiang, Deyi Chen, Zhaolun Li","doi":"10.1007/s13691-024-00734-x","DOIUrl":"10.1007/s13691-024-00734-x","url":null,"abstract":"<p><p>Mismatch repair deficiency (MMRd) or microsatellite instability high (MSI-H) is rare in prostate cancer and more frequently observed in cases with ductal histology. MLH1 copy number loss is extremely rare in MMRd tumors. Herein, we describe a case of prostate ductal adenocarcinoma with MLH1 copy number loss, microsatellite instability high and BRCA2 mutation could derive benefit from immunotherapy plus ADT. A 72-year-old Chinese patient was diagnosed with poorly differentiated prostate ductal adenocarcinoma mixed with acinar adenocarcinoma (Gleason 5 + 4). Next-generation sequencing (NGS) showed a hypermutated tumor with a mutational burden of 34.71 mutations per Mb and microsatellite instability high (MSI-H). Suspected biallelic MLH1 loss (copy number 0.16) and a pathogenic somatic BRCA2 variant (E2981Kfs*7) were detected. After surgery, the patient received androgen-deprivation therapy (ADT) with goserelin (10.8 mg every 3 months) and tislelizumab (200 mg every 3 weeks). At the 1-year follow-up, the PSA level was lower than 0.01 ng/ml and a pelvic MRI revealed no abnormalities. Our case highlights the intricate molecular mechanisms of MMRd prostate cancer.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"46-49"},"PeriodicalIF":0.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}